Bacterial Pneumonia Market, By Type (Hospital-Acquired Pneumonia (HAP) and Community-Acquired Pneumonia (CAP)), By Treatments, By Patient Type, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5203
|
Published Date
May 2026
|
Pages
340
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Bacterial Pneumonia Market size was valued at US$ 2,501.34 Million in 2025, expanding at a CAGR of 8.69% from 2026 to 2033.
Bacterial pneumonia is a lung infection caused by harmful bacteria that inflame the air sacs in the lungs. These air sacs may fill with fluid or pus, leading to breathing difficulties, chest pain, fever, cough, chills, and fatigue. The condition can affect individuals across all age groups; however, young children, elderly individuals, and people with weakened immune systems are at higher risk of severe complications. Common causative bacteria include Streptococcus pneumoniae and Haemophilus influenzae. Standard treatment typically involves antibiotics, supplemental oxygen, adequate hydration, and supportive care.
The bacterial pneumonia market is receiving increasing healthcare attention as governments and medical organizations strengthen respiratory infection prevention and treatment programs worldwide. The World Health Organization reported that pneumonia caused more than 740,000 deaths among children under five globally in 2019, highlighting the need for stronger vaccination and early diagnosis initiatives. The Centers for Disease Control and Prevention also notes that pneumococcal disease remains a significant cause of pneumonia-related hospitalizations among adults and older populations. Governments are increasingly expanding immunization programs, antibiotic access, and respiratory care infrastructure to improve disease outcomes. In parallel, pharmaceutical companies are investing in vaccine development and advanced diagnostic solutions for respiratory infections.
Bacterial Pneumonia Market- Market Dynamics
Increasing burden of respiratory infections and rising hospital admissions driving treatment demand
The rising number of respiratory infections and pneumonia-related hospital admissions in developing and densely populated regions is encouraging healthcare providers to strengthen bacterial pneumonia diagnosis and treatment services. Factors such as air pollution, overcrowded living conditions, smoking exposure, seasonal infections, and weakened immunity among elderly and pediatric populations are contributing to increased demand for respiratory care solutions.
According to the World Health Organization, pneumonia caused more than 740,000 deaths among children under the age of five in 2019, with the majority of cases occurring in developing countries. In India, the Ministry of Health and Family Welfare is actively expanding vaccination programs to prevent pneumonia and related respiratory infections. Companies such as Serum Institute of India and Cipla are supporting vaccine production and improving access to respiratory therapies. In addition, growing awareness regarding early diagnosis and timely antibiotic treatment is encouraging broader adoption of healthcare services across hospitals and community health centers.
Bacterial Pneumonia Market- Segmentation Analysis:
The Global Bacterial Pneumonia Market is segmented on the basis of Type, treatment, Patient Type, Distribution Channel, and Region.
Among treatment options, vaccines are expected to receive significant healthcare attention due to the growing focus on preventing respiratory infections. Governments and healthcare organizations are expanding immunization programs to reduce hospitalizations caused by pneumococcal infections, particularly among children and elderly populations. According to the World Health Organization, pneumonia caused more than 740,000 deaths among children under five globally in 2019, reinforcing the importance of preventive vaccination programs. In India, the Pneumococcal Conjugate Vaccine has been included in the Universal Immunization Programme to strengthen protection against bacterial respiratory infections. Companies such as Pfizer Inc., Merck & Co., and GlaxoSmithKline continue to invest in the research and development of pneumococcal vaccines. Increasing awareness of preventive healthcare, along with government-led vaccination initiatives, is further driving adoption.
Based on patient groups, the geriatric population is expected to witness substantial healthcare attention in the bacterial pneumonia market due to weakened immunity, chronic respiratory conditions, and higher hospitalization risk among older adults. Aging populations across several countries are prompting healthcare systems to strengthen vaccination coverage, respiratory monitoring, and infection management services for elderly individuals. The World Health Organization notes that older adults remain more vulnerable to severe pneumococcal disease and pneumonia-related complications. In Japan, government health agencies continue to promote adult pneumococcal vaccination programs for senior citizens to reduce severe respiratory infections. Companies such as Pfizer Inc. and Merck & Co. are expanding access to pneumococcal vaccines and respiratory health programs targeting elderly populations.
Bacterial Pneumonia Market- Geographical Insights
Across the Asia Pacific, healthcare systems are steadily strengthening respiratory disease prevention and treatment programs, creating supportive conditions for continued growth in the bacterial pneumonia market. Countries across the region are expanding childhood immunization coverage, hospital-based respiratory care services, and infection surveillance systems to reduce the burden of severe lung infections. Government-led healthcare initiatives in India, China, and several Southeast Asian nations are improving access to pneumococcal vaccines, antibiotic therapies, and early diagnostic support. According to the World Health Organization, pneumonia accounted for more than 740,000 deaths among children under five globally in 2019, emphasizing the continued need for stronger respiratory healthcare interventions.
Within the region, India has established a structured public health approach through the Universal Immunization Programme, which includes the Pneumococcal Conjugate Vaccine to enhance protection against bacterial pneumonia and related infections. Government health initiatives have also improved oxygen availability and pediatric respiratory care infrastructure. From an industry perspective, companies such as Pfizer Inc., GlaxoSmithKline, and Serum Institute of India continue to support vaccine access and respiratory infection management across the region. This combination of public health expansion, immunization programs, and pharmaceutical involvement is helping strengthen diagnosis, prevention, and treatment services for bacterial pneumonia across Asia Pacific countries.
China Bacterial Pneumonia Market- Country Insights
China is continuing to strengthen its respiratory healthcare system through expanded vaccination coverage, hospital modernization, and infectious disease monitoring programs linked to bacterial pneumonia management. The government has enhanced public health surveillance and immunization efforts through the National Health Commission of the People\'s Republic of China and the Chinese Center for Disease Control and Prevention. According to the World Health Organization, pneumonia remains a significant cause of hospitalization among children and older adults in many Asian countries, highlighting the need for continued investment in respiratory healthcare systems. Pharmaceutical companies such as Sinovac Biotech and Walvax Biotechnology are also involved in vaccine development and infectious disease prevention programs.
In addition, China is promoting the rational use of antibiotics and expanding laboratory testing capacity to reduce complications from bacterial respiratory infections. Government-supported healthcare reforms are improving intensive care services, oxygen infrastructure, and early disease diagnosis systems. The Chinese CDC continues to promote respiratory infection awareness and disease reporting initiatives across healthcare institutions, supporting improved preparedness and gradual enhancement of bacterial pneumonia prevention and treatment access nationwide
Bacterial Pneumonia Market- Competitive Landscape:
The bacterial pneumonia market is shaped by the active participation of pharmaceutical manufacturers, vaccine developers, and respiratory healthcare providers focused on improving patient care and infection management. Organizations are strengthening their market position through advancements in pneumococcal vaccines, antibiotic therapies, digital diagnostic technologies, and hospital-based respiratory care solutions. Major companies operating in this space include Pfizer Inc., Merck & Co., Sanofi, GlaxoSmithKline, AstraZeneca, and Shanghai Fosun Pharmaceutical. In 2025, Merck & Co. received European approval for CAPVAXIVE, a pneumococcal vaccine developed to support adult pneumonia prevention initiatives. At the same time, Sanofi strengthened its respiratory vaccine pipeline through the acquisition of Vicebio to advance infectious disease research. Rising awareness of antimicrobial resistance surveillance, expanded vaccination efforts, and improvements in respiratory treatment technologies are helping healthcare systems enhance the management of bacterial pneumonia patients.
Recent Developments
- In December 2025, BioVersys initiated a Phase 3 clinical program for BV100 targeting ventilator-associated bacterial pneumonia caused by multidrug-resistant bacteria. The study aims to strengthen hospital infection management and advance treatment options for severe pneumonia cases.
- In October 2025, GPN Vaccines completed the acquisition of BacVax to expand its vaccine development capabilities targeting bacterial infections linked to respiratory complications and chronic pulmonary conditions, strengthening its respiratory vaccine research portfolio globally.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BACTERIAL PNEUMONIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline (GSK)
- Sanofi
- AstraZeneca PLC
- Novartis AG
- Bayer AG
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Shionogi & Co., Ltd.
- bioMérieux SA
- Cipla Limited
- Lupin Limited
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Nabriva Therapeutics plc
- Cumberland Pharmaceuticals Inc.
- Basilea Pharmaceutica Ltd.
- Eagle Pharmaceuticals, Inc.
- Innoviva Specialty Therapeutics, Inc.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Others
GLOBAL BACTERIAL PNEUMONIA MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Hospital-Acquired Pneumonia (HAP)
- Klebsiella Pneumoniae
- Enterobacter Spp
- Acinetobacter Baumannii
- Staphylococcus Aureus
- Aeruginosa
- Community-Acquired Pneumonia (CAP)
- Streptococcus Pneumoniae
- Haemophilus Influenzae
- Mycoplasma Pneumophila
- Chlamydia Pneumoniae
GLOBAL BACTERIAL PNEUMONIA MARKET, BY TREATMENTS- MARKET ANALYSIS, 2020 - 2033
- Drugs
- Vaccines
GLOBAL BACTERIAL PNEUMONIA MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2020 - 2033
- Pediatric Patients
- Adult Patients
- Geriatric Patients
GLOBAL BACTERIAL PNEUMONIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacies
- Online Pharmacies
- Hospitals Pharmacies
- Others
GLOBAL BACTERIAL PNEUMONIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Bacterial Pneumonia Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Bacterial Pneumonia Market Snippet by Type
2.1.2. Bacterial Pneumonia Market Snippet by Treatments
2.1.3. Bacterial Pneumonia Market Snippet by Patient Type
2.1.4. Bacterial Pneumonia Market Snippet by Distribution Channel
2.1.5. Bacterial Pneumonia Market Snippet by Country
2.1.6. Bacterial Pneumonia Market Snippet by Region
2.2. Competitive Insights
3. Bacterial Pneumonia Key Market Trends
3.1. Bacterial Pneumonia Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Bacterial Pneumonia Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Bacterial Pneumonia Market Opportunities
3.4. Bacterial Pneumonia Market Future Trends
4. Bacterial Pneumonia Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Bacterial Pneumonia Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Bacterial Pneumonia Market Landscape
6.1. Bacterial Pneumonia Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Bacterial Pneumonia Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
7.1.2. Hospital-Acquired Pneumonia (HAP)
7.1.2.1. Klebsiella Pneumoniae
7.1.2.2. Enterobacter Spp
7.1.2.3. Acinetobacter Baumannii
7.1.2.4. Staphylococcus Aureus
7.1.2.5. Aeruginosa
7.1.3. Community-Acquired Pneumonia (CAP)
7.1.3.1. Streptococcus Pneumoniae
7.1.3.2. Haemophilus Influenzae
7.1.3.3. Mycoplasma Pneumophila
7.1.3.4. Chlamydia Pneumoniae
8. Bacterial Pneumonia Market – By Treatments
8.1. Overview
8.1.1. Segment Share Analysis, By Treatments, 2025 & 2033 (%)
8.1.2. Drugs
8.1.3. Vaccines
9. Bacterial Pneumonia Market – By Patient Type
9.1. Overview
9.1.1. Segment Share Analysis, By Patient Type, 2025 & 2033 (%)
9.1.2. Pediatric Patients
9.1.3. Adult Patients
9.1.4. Geriatric Patients
10. Bacterial Pneumonia Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
10.1.2. Retail Pharmacies
10.1.3. Online Pharmacies
10.1.4. Hospitals Pharmacies
10.1.5. Others
11. Bacterial Pneumonia Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Bacterial Pneumonia Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Bacterial Pneumonia Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.17. Denmark
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.17.4. Denmark Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.17.5. Denmark Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.17.6. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.18. Rest of Europe
11.3.18.1. Overview
11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.18.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.18.4. Rest of the Europe Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.3.18.5. Rest of the Europe Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Bacterial Pneumonia Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.16. Taiwan
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.16.4. Taiwan Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.16.5. Taiwan Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.16.6. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.17. Vietnam
11.4.17.1. Overview
11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.17.3. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.17.4. Vietnam Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.17.5. Vietnam Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.17.6. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.18. Rest of APAC
11.4.18.1. Overview
11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.18.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.18.4. Rest of APAC Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.4.18.5. Rest of APAC Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Bacterial Pneumonia Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Bacterial Pneumonia Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.14. Iran
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.14.4. Iran Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.14.5. Iran Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.14.6. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.15. Qatar
11.6.15.1. Overview
11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.15.3. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.15.4. Qatar Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.15.5. Qatar Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.15.6. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.16. Rest of MEA
11.6.16.1. Overview
11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.16.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.16.4. Rest of MEA Market Size and Forecast, By Treatments, 2020 - 2033 (US$ Million)
11.6.16.5. Rest of MEA Market Size and Forecast, By Patient Type, 2020 - 2033 (US$ Million)
11.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Bacterial Pneumonia Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Pfizer Inc.
12.2.2. Merck & Co., Inc.
12.2.3. GlaxoSmithKline (GSK)
12.2.4. Sanofi
12.2.5. AstraZeneca PLC
12.2.6. Novartis AG
12.2.7. Bayer AG
12.2.8. AbbVie Inc.
12.2.9. Takeda Pharmaceutical Company Limited
12.2.10. Shionogi & Co., Ltd.
12.2.11. bioMérieux SA
12.2.12. Cipla Limited
12.2.13. Lupin Limited
12.2.14. Teva Pharmaceutical Industries Ltd.
12.2.15. Paratek Pharmaceuticals, Inc.
12.2.16. Melinta Therapeutics, Inc.
12.2.17. Nabriva Therapeutics plc
12.2.18. Cumberland Pharmaceuticals Inc.
12.2.19. Basilea Pharmaceutica Ltd.
12.2.20. Eagle Pharmaceuticals, Inc.
12.2.21. Innoviva Specialty Therapeutics, Inc.
12.2.22. Abbott Laboratories
12.2.23. F. Hoffmann-La Roche Ltd.
12.2.24. Sun Pharmaceutical Industries Ltd.
12.2.25. Aurobindo Pharma Limited
12.2.26. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BACTERIAL PNEUMONIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline (GSK)
- Sanofi
- AstraZeneca PLC
- Novartis AG
- Bayer AG
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Shionogi & Co., Ltd.
- bioMérieux SA
- Cipla Limited
- Lupin Limited
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Nabriva Therapeutics plc
- Cumberland Pharmaceuticals Inc.
- Basilea Pharmaceutica Ltd.
- Eagle Pharmaceuticals, Inc.
- Innoviva Specialty Therapeutics, Inc.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Others
GLOBAL BACTERIAL PNEUMONIA MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Hospital-Acquired Pneumonia (HAP)
- Klebsiella Pneumoniae
- Enterobacter Spp
- Acinetobacter Baumannii
- Staphylococcus Aureus
- Aeruginosa
- Community-Acquired Pneumonia (CAP)
- Streptococcus Pneumoniae
- Haemophilus Influenzae
- Mycoplasma Pneumophila
- Chlamydia Pneumoniae
GLOBAL BACTERIAL PNEUMONIA MARKET, BY TREATMENTS- MARKET ANALYSIS, 2020 - 2033
- Drugs
- Vaccines
GLOBAL BACTERIAL PNEUMONIA MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2020 - 2033
- Pediatric Patients
- Adult Patients
- Geriatric Patients
GLOBAL BACTERIAL PNEUMONIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacies
- Online Pharmacies
- Hospitals Pharmacies
- Others
GLOBAL BACTERIAL PNEUMONIA MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
